Endologix, Inc. (NASDAQ:ELGX) – Analysts at Piper Jaffray Companies issued their Q1 2021 earnings estimates for Endologix in a research report issued on Wednesday, November 6th. Piper Jaffray Companies analyst M. O’brien expects that the medical instruments supplier will post earnings per share of ($0.23) for the quarter. Piper Jaffray Companies also issued estimates for Endologix’s Q2 2021 earnings at ($0.18) EPS, Q3 2021 earnings at ($0.20) EPS and FY2022 earnings at ($0.76) EPS.
Endologix (NASDAQ:ELGX) last released its quarterly earnings data on Wednesday, November 6th. The medical instruments supplier reported ($0.55) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.63) by $0.08. The business had revenue of $35.78 million during the quarter, compared to analysts’ expectations of $35.26 million. Endologix had a negative net margin of 60.32% and a negative return on equity of 120.57%.
Shares of Endologix stock traded up $0.12 during trading on Friday, hitting $3.00. 196,400 shares of the stock were exchanged, compared to its average volume of 230,126. The stock has a market cap of $48.61 million, a price-to-earnings ratio of -0.42 and a beta of 0.26. The company has a debt-to-equity ratio of 2.45, a current ratio of 2.53 and a quick ratio of 1.80. The firm’s 50-day moving average price is $3.44 and its 200 day moving average price is $5.71. Endologix has a 12-month low of $2.28 and a 12-month high of $12.95.
A number of institutional investors have recently made changes to their positions in the business. First Light Asset Management LLC acquired a new position in Endologix in the second quarter valued at approximately $17,828,000. Morgan Stanley grew its position in shares of Endologix by 1,395.2% during the second quarter. Morgan Stanley now owns 722,419 shares of the medical instruments supplier’s stock worth $5,230,000 after purchasing an additional 674,103 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Endologix by 32.6% during the second quarter. Vanguard Group Inc. now owns 692,351 shares of the medical instruments supplier’s stock worth $5,012,000 after purchasing an additional 170,316 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Endologix by 868.3% during the second quarter. Renaissance Technologies LLC now owns 613,906 shares of the medical instruments supplier’s stock worth $4,445,000 after purchasing an additional 550,506 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. grew its position in shares of Endologix by 6.9% during the second quarter. D. E. Shaw & Co. Inc. now owns 177,931 shares of the medical instruments supplier’s stock worth $1,288,000 after purchasing an additional 11,497 shares in the last quarter. 77.88% of the stock is currently owned by hedge funds and other institutional investors.
Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system.
Further Reading: Stocks Increasing Dividends
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.